In summary, we hypothesise that adaptive phosphorylation of ERK might be a potential mechanism of cellular defence to cetuximab and radiotherapy in HNSCC, suggesting potential benefits of combining current therapeutic strategies with targeted therapy against MEK-ERK signalling. This evidence concerns the gene MAP2K7 and head and neck squamous cell carcinoma.